Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Recombinant activated factor VII

Factor VIIa (recombinant)

Brand names: NovoSeven

Recombinant activated factor VII is a haemostatic agent used to control bleeding, particularly in haemophilia patients with inhibitors and certain other bleeding disorders.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It acts at the site of vascular injury, complexing with tissue factor and directly activating coagulation on the surface of activated platelets to generate thrombin and a fibrin clot.

Prescribing in practice

  • It carries a risk of arterial and venous thromboembolic events, so it should be used cautiously in patients with risk factors for thrombosis or disseminated intravascular coagulation.
  • It should be used within its licensed indications and under specialist guidance because of its potent procoagulant effect.
  • Treatment is guided by clinical haemostatic response rather than routine laboratory monitoring, and repeated dosing may be required for ongoing bleeding.

Monitoring

Monitor the clinical haemostatic response and watch for signs of thrombosis rather than relying on standard coagulation tests.

Counselling the patient

  • Report symptoms suggesting a clot, such as chest pain, breathlessness or limb swelling, straight away.
  • Tell your team about any history of clots, heart disease or stroke.

Evidence & guidelines

Recombinant activated factor VII is established for bleeding in haemophilia with inhibitors and used within specialist haematology practice.

Reference: UKHCDO; NICE evidence summary; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways